EUR-Lex Πρόσβαση στο δίκαιο της Ευρωπαϊκής Ένωσης
Το έγγραφο αυτό έχει ληφθεί από τον ιστότοπο EUR-Lex
Έγγραφο E2014G1009(01)
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2011
Ravimid – EMP EFTA riikide poolt 2011. aasta teisel poolaastal antud müügilubade nimekiri
Ravimid – EMP EFTA riikide poolt 2011. aasta teisel poolaastal antud müügilubade nimekiri
ELT C 356, 9.10.2014, σ. 7 έως 21
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
9.10.2014 |
ET |
Euroopa Liidu Teataja |
C 356/7 |
Ravimid – EMP EFTA riikide poolt 2011. aasta teisel poolaastal antud müügilubade nimekiri
2014/C 356/06
Kaupade vaba liikumise I allkomitee
Teadmiseks EMP ühiskomiteele
Vastavalt EMP ühiskomitee 28. mai 1999. aasta otsusele nr 74/1999 kutsutakse EMP ühiskomiteed 15. juunil 2012 toimuval koosolekul arvesse võtma järgmisi ajavahemikus 1. juulist – 31. detsembrini 2011 antud ravimite müügilubade nimekirju:
I lisa |
Uute müügilubade nimekiri |
II lisa |
Uuendatud müügilubade nimekiri |
III lisa |
Pikendatud müügilubade nimekiri |
IV lisa |
Äravõetud müügilubade nimekiri |
V lisa |
Peatatud müügilubade nimekiri |
I LISA
Uute müügilubade nimekiri
Ajavahemikus 1. juulist – 31. detsembrini 2011 anti EMP EFTA riikides välja järgmised müügiload:
ELi number |
Toode |
Riik |
Loa väljaandmise kuupäev |
EU/1/09/543/001–002 |
Cayston (1) |
Liechtenstein |
31.10.2011 |
EU/1/10/642/001–004 |
Ibandronic Acid Teva |
Norra |
23.8.2011 |
EU/1/10/649/001–016 |
Clopidogrel Teva Pharma B.V |
Norra |
19.7.2011 |
EU/1/10/649/001–016 |
Clopidogrel Teva Pharma B.V. |
Liechtenstein |
31.8.2011 |
EU/1/10/652/001–003 |
TOBI Podhaler |
Liechtenstein |
31.8.2011 |
EU/1/10/652/001–003 |
TOBI Podhaler |
Norra |
17.8.2011 |
EU/1/10/652/001–003 |
TOBI Podhaler |
Island |
9.8.2011 |
EU/1/10/654/001–004 |
Leflunomide ratiopharm |
Norra |
25.8.2011 |
EU/1/10/660/001–002 |
Potactasol |
Norra |
24.8.2011 |
EU/1/10/661/001–002 |
Fluenz |
Norra |
23.8.2011 |
EU/1/11/672/001–006 |
Xeplion |
Liechtenstein |
31.10.2011 |
EU/1/11/683/001–080 |
Sprimeo HCT |
Liechtenstein |
31.8.2011 |
EU/1/11/683/001–080 |
Sprimeo HCT |
Norra |
22.8.2011 |
EU/1/11/683/001–080 |
Sprimeo HCT |
Island |
10.8.2011 |
EU/1/11/685/001–005 |
Ibandronic acid Sandoz |
Liechtenstein |
31.8.2011 |
EU/1/11/685/001–005 |
Ibandronic acid Sandoz |
Island |
18.8.2011 |
EU/1/11/689/001–002 |
IOA |
Liechtenstein |
31.12.2011 |
EU/1/11/689/001–002 |
IOA |
Norra |
6.12.2011 |
EU/1/11/689/001–002 |
Ioa |
Island |
25.11.2011 |
EU/1/11/690/001–002 |
Zoely |
Liechtenstein |
31.8.2011 |
EU/1/11/690/001–002 |
Zoely |
Norra |
18.8.2011 |
EU/1/11/690/001–002 |
Zoely |
Island |
9.8.2011 |
EU/1/11/691/001–005 |
Eliquis |
Island |
8.8.2011 |
EU/1/11/693/001–016 |
Rivastigmin Actavis |
Norra |
19.8.2011 |
EU/1/11/694/001–002 |
Nulojix |
Liechtenstein |
31.8.2011 |
EU/1/11/694/001–002 |
Nulojix |
Norra |
1.8.2011 |
EU/1/11/694/001–002 |
Nulojix |
Island |
6.7.2011 |
EU/1/11/695/001–055 |
Leganto |
Liechtenstein |
31.8.2011 |
EU/1/11/695/001–055 |
Leganto |
Norra |
23.8.2011 |
EU/1/11/695/001–055 |
Leganto |
Island |
6.7.2011 |
EU/1/11/696/001–002 |
Bydureon |
Norra |
5.7.2011 |
EU/1/11/696/001–002 |
Bydureon |
Island |
6.7.2011 |
EU/1/11/696/001–002 |
Bydureon |
Liechtenstein |
31.8.2011 |
EU/1/11/697/001–012 |
Temozolomide Sun |
Liechtenstein |
31.8.2011 |
EU/1/11/697/001–012 |
Temozolomide SUN |
Norra |
22.8.2011 |
EU/1/11/697/001–012 |
Temozolomide SUN |
Island |
9.8.2011 |
EU/1/11/698/001–002 |
Yervoy |
Liechtenstein |
31.8.2011 |
EU/1/11/698/001–002 |
Yervoy |
Norra |
18.8.2011 |
EU/1/11/698/001–002 |
Yervoy |
Island |
21.7.2011 |
EU/1/11/699/001–002 |
Fampyra |
Liechtenstein |
31.8.2011 |
EU/1/11/699/001–002 |
Fampyra |
Norra |
23.8.2011 |
EU/1/11/699/001–002 |
Fampyra |
Island |
9.8.2011 |
EU/1/11/700/001–002 |
Benlysta |
Liechtenstein |
31.8.2011 |
EU/1/11/700/001–002 |
Benlysta |
Norra |
27.7.2011 |
EU/1/11/700/001–002 |
Benlysta |
Island |
21.7.2011 |
EU/1/11/701/001–028 |
Levetiracetam Teva |
Liechtenstein |
31.10.2011 |
EU/1/11/701/001–028 |
Levetiracetam Teva |
Norra |
26.9.2011 |
EU/1/11/701/001–028 |
Levetiracetam Teva |
Island |
16.9.2011 |
EU/1/11/702/001–031 |
Levetiracetam Ratiopharm |
Liechtenstein |
31.10.2011 |
EU/1/11/702/001–031 |
Levetiracetam ratiopharm |
Norra |
26.9.2011 |
EU/1/11/702/001–031 |
Levetiracetam ratiopharm |
Island |
16.9.2011 |
EU/1/11/703/001–002 |
Xgeva |
Liechtenstein |
31.8.2011 |
EU/1/11/703/001–002 |
Xgeva |
Norra |
15.8.2011 |
EU/1/11/703/001–002 |
XGEVA |
Island |
21.7.2011 |
EU/1/11/704/001 |
Victrelis |
Liechtenstein |
31.8.2011 |
EU/1/11/704/001 |
Victrelis |
Norra |
16.8.2011 |
EU/1/11/704/001 |
Victrelis |
Island |
10.8.2011 |
EU/1/11/705/001–002 |
Vibativ |
Liechtenstein |
31.10.2011 |
EU/1/11/705/001–002 |
Vibativ |
Norra |
19.9.2011 |
EU/1/11/705/001–002 |
Vibativ |
Island |
16.9.2011 |
EU/1/11/706/001–033 |
Levodopa/Cardidopa/Entacapone Orion |
Liechtenstein |
31.10.2011 |
EU/1/11/706/001–033 |
Levodopa/Carbidopa/Entacapone Orion |
Norra |
23.9.2011 |
EU/1/11/706/001–033 |
Levodopa/Carbidopa/Entacapone Orion |
Island |
14.9.2011 |
EU/1/11/707/001–011 |
Trajenta |
Liechtenstein |
31.10.2011 |
EU/1/11/707/001–011 |
Trajenta |
Norra |
12.9.2011 |
EU/1/11/707/001–011 |
Trajenta |
Island |
14.9.2011 |
EU/1/11/708/001–004 |
Entacapone Orion |
Liechtenstein |
31.8.2011 |
EU/1/11/708/001–004 |
Entacapone Orion |
Norra |
22.9.2011 |
EU/1/11/708/001–004 |
Entacapone Orion |
Island |
26.8.2011 |
EU/1/11/709/001–004 |
Buccolam |
Norra |
27.9.2011 |
EU/1/11/709/001–03 |
Buccolam |
Island |
1.11.2011 |
EU/1/11/710/001–007 |
Votubia |
Liechtenstein |
31.10.2011 |
EU/1/11/710/001–007 |
Votubia |
Norra |
15.9.2011 |
EU/1/11/710/001–007 |
Votubia |
Island |
16.9.2011 |
EU/1/11/711/001–030 |
Matever |
Liechtenstein |
31.10.2011 |
EU/1/11/711/001–030 |
Matever |
Island |
13.10.2011 |
EU/1/11/712/001–028 |
Levetiracetam Accord |
Liechtenstein |
31.10.2011 |
EU/1/11/712/001–028 |
Levetiracetam Accord |
Island |
6.11.2011 |
EU/1/11/713/001–040 |
Levetiracetam Actavis |
Liechtenstein |
31.10.2011 |
EU/1/11/713/001–040 |
Levetiracetam Actavis |
Island |
13.10.2011 |
EU/1/11/714/001 |
Zytiga |
Liechtenstein |
31.10.2011 |
EU/1/11/714/001 |
Zytiga |
Norra |
26.9.2011 |
EU/1/11/714/001 |
Zytiga 250 mg Tafla |
Island |
19.9.2011 |
EU/1/11/715/001–002 |
Plenadren |
Liechtenstein |
31.12.2011 |
EU/1/11/715/001–002 |
Plenadren |
Norra |
25.11.2011 |
EU/1/11/716/001–005 |
Eurartesim |
Liechtenstein |
31.12.2011 |
EU/1/11/716/001–005 |
Eurartesim |
Norra |
21.12.2011 |
EU/1/11/716/001–005 |
Eurartesim |
Island |
10.11.2011 |
EU/1/11/717/001 |
Vyndaqel |
Liechtenstein |
31.12.2011 |
EU/1/11/717/001 |
Vyndaqel |
Norra |
6.12.2011 |
EU/1/11/717/001 |
Vyndaqel |
Island |
25.11.2011 |
EU/1/11/718/001–006 |
Dexdor |
Liechtenstein |
31.10.2011 |
EU/1/11/718/001–006 |
Dexdor |
Norra |
11.10.2011 |
EU/1/11/718/001–006 |
Dexdor |
Island |
30.9.2011 |
EU/1/11/719/001–060 |
Telmisartan Teva Pharma |
Norra |
18.10.2011 |
EU/1/11/719/001–060 |
Telmisartan Teva Pharma |
Island |
6.11.2011 |
EU/1/11/720/001 |
Incivo |
Liechtenstein |
31.10.2011 |
EU/1/11/720/001 |
Incivo |
Norra |
6.10.2011 |
EU/1/11/720/001 |
Incivo 375 mg Filmuhúðuð tafla |
Island |
8.10.2011 |
EU/1/11/728/001–010 |
Pramipexole Accord |
Liechtenstein |
31.10.2011 |
EU/1/11/728/001–010 |
Pramipexole Accord |
Norra |
18.10.2011 |
EU/1/11/728/001–010 |
Pramipexole Accord |
Island |
10.10.2011 |
EU/1/11/729/001–006 |
Onduarp |
Liechtenstein |
31.12.2011 |
EU/1/11/729/001–006 |
Onduarp |
Island |
14.12.2011 |
EU/1/11/730/001–060 |
Rasitrio |
Norra |
7.12.2011 |
EU/1/11/731/001–012 |
Komboglyze |
Liechtenstein |
31.12.2011 |
EU/1/11/731/001–012 |
Komboglyze |
Norra |
15.12.2011 |
EU/1/11/731/001–012 |
Komboglyze |
Island |
8.12.2011 |
EU/1/11/732/001–013 |
Desloratadine Teva |
Liechtenstein |
31.12.2011 |
EU/1/11/732/001–013 |
Desloratadine Teva |
Norra |
20.12.2011 |
EU/1/11/732/001–013 |
Desloratadine Teva |
Island |
8.12.2011 |
EU/1/11/733/001–004 |
Dificlir |
Liechtenstein |
31.12.2011 |
EU/1/11/733/001–004 |
Dificlir |
Norra |
20.12.2011 |
EU/1/11/733/001–004 |
Dificlir |
Island |
14.12.2011 |
EU/1/11/734/001–011 |
Edarbi |
Liechtenstein |
31.12.2011 |
EU/1/11/734/001–011 |
Edarbi |
Norra |
21.12.2011 |
EU/1/11/734/001–011 |
Edarbi |
Island |
17.12.2011 |
EU/1/11/735/001–011 |
Ipreziv |
Liechtenstein |
31.12.2011 |
EU/1/11/735/001–011 |
Ipreziv |
Norra |
21.12.2011 |
EU/1/11/735/001–011 |
Ipreziv |
Island |
17.12.2011 |
EU/1/11/736/001 |
Edurant |
Liechtenstein |
31.12.2011 |
EU/1/11/736/001 |
Edurant |
Norra |
6.12.2011 |
EU/1/11/736/001 |
EDURANT |
Island |
14.12.2011 |
EU/1/11/737/001–002 |
Eviplera |
Liechtenstein |
31.12.2011 |
EU/1/11/737/001–002 |
Eviplera |
Norra |
6.12.2011 |
EU/1/11/737/001–002 |
Eviplera |
Island |
14.12.2011 |
EU/1/11/738/001–003 |
Levetiracetam Actavis Group |
Liechtenstein |
31.12.2011 |
EU/1/11/738/001–003 |
Levetiracetam Actavis Group |
Island |
14.12.2011 |
EU/1/11/739/001–008 |
Dasselta |
Liechtenstein |
31.12.2011 |
EU/1/11/739/001–008 |
Dasselta |
Island |
8.12.2011 |
EU/1/11/740/001 |
Ameluz |
Liechtenstein |
31.12.2011 |
EU/2/07/078/011–014 |
Rheumocam |
Norra |
6.7.2011 |
EU/2/10/110/001–002 |
Coxevac |
Norra |
22.8.2011 |
EU/2/10/112/001–005 |
BTVPUR AlSap 1 |
Norra |
22.8.2011 |
EU/2/10/113/001–005 |
BTVPUR AlSap 1–8 |
Norra |
23.8.2011 |
EU/2/11/122/001–003 |
Bluevac BTV8 |
Island |
12.7.2011 |
EU/2/11/124/001–008 |
Zuprevo |
Norra |
6.7.2011 |
EU/2/11/125/001–008 |
Certifect |
Norra |
1.9.2011 |
EU/2/11/126/001 |
MS-H-vaksine – Mycoplasma synoviae |
Norra |
5.7.2011 |
EU/2/11/127/001 |
Recuvyra |
Norra |
6.12.2011 |
EU/2/11/127/001 |
RECUVYRA |
Island |
11.11.2011 |
EU/2/11/128/001–003 |
Emdocam |
Norra |
14.9.2011 |
EU/2/11/128/001–003 |
Emdocam |
Island |
8.9.2011 |
EU/2/11/129/001–004 |
Proteq West Nile |
Norra |
19.8.2011 |
EU/2/11/129/001–004 |
Proteq West Nile |
Island |
12.8.2011 |
EU/2/11/130/001–003 |
Zulvac 1 Bovis |
Norra |
17.8.2011 |
EU/2/11/130/001–003 |
Zulvac 1 Bovis |
Island |
18.8.2011 |
EU/2/11/131/001–006 |
Zulvac 1 Ovis |
Norra |
17.8.2011 |
EU/2/11/131/001–006 |
Zulvac 1 Ovis |
Island |
12.8.2011 |
EU/2/11/132/001–004 |
Nobivac Myxo-RHD |
Norra |
19.9.2011 |
EU/2/11/132/001–004 |
Nobivac Myxo-RHD |
Island |
20.9.2011 |
EU/2/11/133/001–003 |
Recocam |
Norra |
6.10.2011 |
EU/2/11/133/001–003 |
Recocam 20 mg/ml |
Island |
23.9.2011 |
EU/2/11/134/001–014 |
Inflacam |
Island |
19.12.2011 |
EU/2/11/135/001–003 |
Panacur AquaSol |
Island |
19.12.2011 |
(1) Tingimuslik müügiluba asendati erikohustusteta müügiloaga.
II LISA
Uuendatud müügilubade nimekiri
Ajavahemikus 1. juulist – 31. detsembrini 2011 uuendati EMP EFTA riikides järgmisi müügilube:
ELi number |
Toode |
Riik |
Loa väljaandmise kuupäev |
EU/1/01/196/001 EU/1/01/196/003 |
Cancidas |
Norra |
20.9.2011 |
EU/1/01/196/001, 003 |
Cancidas |
Island |
20.9.2011 |
EU/1/01/196/001, 003 |
Cancidas |
Liechtenstein |
31.10.2011 |
EU/1/01/200/001–002 |
Viread |
Liechtenstein |
31.12.2011 |
EU/1/06/336/001 |
Tygacil |
Island |
13.7.2011 |
EU/1/06/340/001–002 |
Ganfort |
Liechtenstein |
31.8.2011 |
EU/1/06/340/001–002 |
Ganfort |
Norra |
1.9.2011 |
EU/1/06/340/001–002 |
Ganfort |
Island |
8.7.2011 |
EU/1/06/342/001 |
Nexavar |
Liechtenstein |
31.8.2011 |
EU/1/06/342/001 |
Nexavar |
Norra |
20.9.2011 |
EU/1/06/342/001 |
Nexavar |
Island |
9.8.2011 |
EU/1/06/343/001–007 |
Baraclude |
Norra |
6.7.2011 |
EU/1/06/346/001 |
Tysabri |
Liechtenstein |
31.8.2011 |
EU/1/06/346/001 |
Tysabri |
Norra |
19.7.2011 |
EU/1/06/35/001–003 |
Livensa |
Liechtenstein |
31.8.2011 |
EU/1/06/350/001 |
Savene |
Liechtenstein |
31.8.2011 |
EU/1/06/350/001 |
Savene |
Norra |
18.8.2011 |
EU/1/06/350/001 |
Savene |
Island |
9.8.2011 |
EU/1/06/351/001–003 |
Livensa |
Norra |
12.8.2011 |
EU/1/06/351/001–003 |
Livensa |
Island |
9.8.2011 |
EU/1/06/352/001–003 |
Intrinsa |
Liechtenstein |
31.8.2011 |
EU/1/06/352/001–003 |
Intrinsa |
Norra |
12.8.2011 |
EU/1/06/352/001–003 |
Intrinsa |
Island |
10.8.2011 |
EU/1/06/355/001–003 |
ATryn |
Liechtenstein |
31.8.2011 |
EU/1/06/355/001–003 |
ATryn |
Norra |
1.9.2011 |
EU/1/06/355/001–003 |
ATryn |
Island |
18.8.2011 |
EU/1/06/356/001–009 |
Exjade |
Liechtenstein |
31.8.2011 |
EU/1/06/356/001–009 |
Exjade |
Norra |
17.8.2011 |
EU/1/06/356/001–009 |
Exjade |
Island |
9.8.2011 |
EU/1/06/357/001–008, 018–021 |
Gardasil |
Island |
11.8.2011 |
EU/1/06/357/001–008 EU/1/06/357/018–021 |
Gardasil |
Norra |
19.8.2011 |
EU/1/06/358/001–008, 018–021 |
Silgard |
Island |
10.8.2011 |
EU/1/06/358/001–021 |
Silgard |
Liechtenstein |
31.8.2011 |
EU/1/06/358/001–021 |
Silgard |
Norra |
12.8.2011 |
EU/1/06/359/001–004 |
Suboxone |
Liechtenstein |
31.10.2011 |
EU/1/06/359/001–004 |
Suboxone |
Norra |
14.10.2011 |
EU/1/06/359/001–004 |
Suboxone |
Island |
4.10.2011 |
EU/1/06/360/001–013 |
Champix |
Norra |
3.8.2011 |
EU/1/06/360/001–013 |
Champix |
Island |
7.7.2011 |
EU/1/06/361/001–002 |
Luminity |
Liechtenstein |
31.10.2011 |
EU/1/06/361/001–002 |
Luminity |
Norra |
21.9.2011 |
EU/1/06/361/001–002 |
Luminity |
Island |
21.9.2011 |
EU/1/06/362/001–004 |
Byetta |
Liechtenstein |
31.10.2011 |
EU/1/06/362/001–004 |
Byetta |
Norra |
6.10.2011 |
EU/1/06/362/001–004 |
Byetta |
Island |
8.10.2011 |
EU/1/06/363/001–015 |
Sprycel |
Liechtenstein |
31.10.2011 |
EU/1/06/363/001–015 |
Sprycel |
Norra |
14.10.2011 |
EU/1/06/363/001–015 |
Sprycel |
Island |
7.11.2011 |
EU/1/06/364/001–004 EU/1/06/364/006–008 |
Adrovance |
Norra |
23.12.2011 |
EU/1/06/364/001–004, 006–008 |
Adrovance |
Island |
7.12.2011 |
EU/1/06/364/006–008 |
Adrovance |
Liechtenstein |
31.12.2011 |
EU/1/06/365/001–003 |
Elaprase |
Liechtenstein |
31.10.2011 |
EU/1/06/365/001–003 |
Elaprase |
Norra |
14.10.2011 |
EU/1/06/365/001–003 |
Elaprase |
Island |
6.11.2011 |
EU/1/06/368/001–015, 020–024, 029–033, 038–042, 047–051, 056–057, 088–102, 113–150, 163–168 |
Insulin Human Winthrop |
Liechtenstein |
31.12.2011 |
EU/1/06/368/001–168 |
Insulin Human Winthrop |
Island |
6.12.2011 |
EU/1/06/370/001–039 |
Exforge |
Liechtenstein |
31.12.2011 |
EU/1/06/372/001–039 |
Copalia |
Liechtenstein |
31.12.2011 |
EU/1/06/372/001–039 |
Copalia |
Island |
7.12.2011 |
EU/1/06/373/001–039 |
Imprida |
Liechtenstein |
31.12.2011 |
EU/1/07/440/001–006 |
Tyverb |
Island |
22.8.2011 |
EU/1/08/468/001 |
Intelence |
Liechtenstein |
31.8.2011 |
EU/1/08/468/001 |
Intelence |
Norra |
17.8.2011 |
EU/1/08/468/001 |
INTELENCE |
Island |
11.8.2011 |
EU/1/09/543/001–002 |
Cayston |
Norra |
19.9.2011 |
EU/1/09/543/001–002 |
Cayston |
Island |
19.9.2011 |
EU/1/10/628/001–004 |
Votrient |
Norra |
21.10.2011 |
EU/1/96/024/001–005 |
Crixivan |
Liechtenstein |
31.8.2011 |
EU/1/96/024/001–005 EU/1/96/024/010 |
Crixivan |
Norra |
18.8.2011 |
EU/1/96/024/001–010 |
Crixivan |
Island |
10.8.2011 |
EU/2/06/059/001 |
Convenia |
Norra |
6.7.2011 |
EU/2/06/060/001–002 |
Poulvac Flufend H5N3 RG |
Island |
11.8.2011 |
EU/2/06/061/001–004 |
Nobilis Influenza H5N2 |
Norra |
14.9.2011 |
EU/2/06/061/001–004 |
Nobilis Influenza H5N2 |
Island |
8.9.2011 |
EU/2/06/062/001–005 |
Cerenia |
Norra |
18.8.2011 |
EU/2/06/062/001–005 |
Cerenia |
Island |
12.8.2011 |
EU/2/06/064/001–004 |
ProMeris |
Norra |
8.12.2011 |
EU/2/06/064/001–004 |
ProMeris |
Island |
21.11.2011 |
EU/2/06/065/001–010 |
ProMeris Duo |
Island |
4.12.2011 |
EU/2/06/065/001–010 |
ProMeris Duo |
Norra |
8.12.2011 |
EU/2/06/066/001–012 |
Prac-Tic |
Norra |
8.12.2011 |
EU/2/06/066/001–012 |
Prac-tic |
Island |
25.11.2011 |
EU/2/06/069/001 |
Cortavance |
Norra |
27.9.2011 |
EU/2/06/069/001 |
Cortavance |
Island |
23.9.2011 |
EU/2/99/016/001–006 |
Porcilis Pesti |
Norra |
6.10.2011 |
EU/2/99/016/001–006 |
Porcilis Pesti |
Island |
7.10.2011 |
III LISA
Pikendatud müügilubade nimekiri
Ajavahemikus 1. juulist – 31. detsembrini 2011 pikendati EMP EFTA riikides järgmised müügiload:
ELi number |
Toode |
Riik |
Loa väljaandmise kuupäev |
EU/1/00/165/008 |
Ovitrelle |
Liechtenstein |
31.8.2011 |
EU/1/00/165/008 |
Ovitrelle |
Norra |
6.7.2011 |
EU/1/01/176/007–009 |
Zometa |
Liechtenstein |
31.10.2011 |
EU/1/01/176/007–009 |
Zometa |
Norra |
12.9.2011 |
EU/1/01/176/007–009 |
Zometa |
Island |
12.11.2011 |
EU/1/02/221/011–016 |
Pegasys |
Liechtenstein |
31.8.2011 |
EU/1/03/248/013–023 |
Levitra |
Liechtenstein |
31.12.2011 |
EU/1/03/249/013–015 |
Vivanza |
Liechtenstein |
31.12.2011 |
EU/1/03/260/034–038 |
Stalevo |
Norra |
23.9.2011 |
EU/1/03/260/034–038 |
Stalevo |
Liechtenstein |
31.10.2011 |
EU/1/03/260/034–038 |
Stalevo |
Island |
13.9.2011 |
EU/1/03/262/009–010 |
Emend |
Liechtenstein |
31.12.2011 |
EU/1/03/270/004–005 |
Kentera |
Liechtenstein |
31.8.2011 |
EU/1/03/270/004–005 |
Kentera |
Norra |
7.9.2011 |
EU/1/03/270/004–005 |
Kentera |
Island |
9.9.2011 |
EU/1/03/271/007–010 |
Advate |
Liechtenstein |
31.12.2011 |
EU/1/05/322/002 |
Yttriga |
Liechtenstein |
31.8.2011 |
EU/1/06/332/010–012 |
Omnitrope |
Norra |
25.8.2011 |
EU/1/06/378/017 |
Inovelon |
Liechtenstein |
31.12.2011 |
EU/1/06/378/017 |
Inovelon |
Norra |
20.12.2011 |
EU/1/07/392/003 |
Circadin |
Liechtenstein |
31.10.2011 |
EU/1/07/401/016 |
Alli |
Liechtenstein |
31.8.2011 |
EU/1/07/422/007–008 |
Tasigna |
Liechtenstein |
31.8.2011 |
EU/1/07/422/009–012 |
Tasigna |
Liechtenstein |
31.12.2011 |
EU/1/08/442/009–013 |
Pradaxa |
Island |
10.8.2011 |
EU/1/08/442/009–014 |
Pradaxa |
Liechtenstein |
31.8.2011 |
EU/1/08/442/009–014 |
Pradaxa |
Norra |
17.8.2011 |
EU/1/08/468/002 |
Intelence |
Liechtenstein |
31.12.2011 |
EU/1/08/468/002 |
Intelence |
Norra |
15.12.2011 |
EU/1/08/470/014–015 |
Vimpat |
Island |
8.12.2011 |
EU/1/08/472/011–021 |
Xarelto |
Liechtenstein |
31.12.2011 |
EU/1/08/472/011–021 |
Xarelto |
Island |
20.12.2011 |
EU/1/09/508/011 |
Synflorix |
Liechtenstein |
31.8.2011 |
EU/1/09/531/010–021 |
Instanyl |
Liechtenstein |
31.8.2011 |
EU/1/09/531/010–021 |
Instanyl |
Norra |
1.8.2011 |
EU/1/09/531/010–021 |
Instanyl |
Island |
13.7.2011 |
EU/1/09/564/003 |
Ilaris |
Liechtenstein |
31.10.2011 |
EU/1/09/564/003 |
Ilaris |
Island |
5.10.2011 |
EU/1/09/564/003 |
Ilaris |
Norra |
27.9.2011 |
EU/1/09/610/031–060 |
Telmisartan Teva |
Liechtenstein |
31.8.2011 |
EU/1/10/614/003 |
Menveo |
Liechtenstein |
31.8.2011 |
EU/1/10/636/004–007 |
Daxas |
Liechtenstein |
31.12.2011 |
EU/1/10/646/003–006 |
VPRIV |
Liechtenstein |
31.8.2011 |
EU/1/10/647/003–004 |
Myclausen |
Norra |
27.9.2011 |
EU/1/10/647/003–004 |
Myclausen |
Island |
3.10.2011 |
EU/1/95/003/011–012 |
Betaferon |
Liechtenstein |
31.8.2011 |
EU/1/97/055/005–009 |
Viramune |
Norra |
14.10.2011 |
EU/1/97/055/005–009 |
Viramune |
Island |
5.10.2011 |
EU/1/98/090/021–022 |
Micardis |
Liechtenstein |
31.8.2011 |
EU/1/99/119/019–023 |
NovoRapid |
Liechtenstein |
31.8.2011 |
EU/1/99/126/022 |
Enbrel |
Island |
13.7.2011 |
EU/2/08/090/010–018 |
Loxicom |
Norra |
15.8.2011 |
EU/2/08/090/010–026 |
Loxicom |
Island |
22.7.2011 |
EU/2/08/090/019–026 |
Loxicom |
Norra |
27.9.2011 |
IV LISA
Äravõetud müügilubade nimekiri
Ajavahemikus 1. juulist – 31. detsembrini 2011 võeti EMP EFTA riikides ära järgmised müügiload:
ELi number |
Toode |
Riik |
Tagasivõtmise kuupäev |
EU/1/02/225/001–002 |
Xigris |
Liechtenstein |
31.12.2011 |
EU/1/03/259/001–006 |
Onsenal |
Norra |
5.8.2011 |
EU/1/05/313/001–009 |
Ablavar |
Liechtenstein |
31.10.2011 |
EU/1/05/313/001–009 |
Ablavar |
Norra |
29.11.2011 |
EU/1/05/313/001–009 |
Ablavar |
Island |
6.11.2011 |
EU/1/08/470/014–015 |
Vimpat |
Island |
8.12.2011 |
EU/1/08/478/001 |
Pandeemiaeelne gripivaktsiin (H5N1) |
Liechtenstein |
31.10.2011 |
EU/1/08/478/001 |
Pandeemiaeelne gripivaktsiin (H5N1) (inaktiveeritud purustatud viirus, adjuveeritud) GlaxoSmithKline Biologicals |
Island |
6.11.2011 |
EU/1/09/547/001–007 |
Clopidogrel Sandoz |
Norra |
5.8.2011 |
EU/1/09/547/001–007 |
Clopidogrel Sandoz |
Island |
23.8.2011 |
EU/1/10/629/001 |
Humenza |
Norra |
5.8.2011 |
EU/2/06/063/001–003 |
Yarvitan |
Norra |
22.9.2011 |
EU/2/06/063/001–003 |
Yarvitan |
Island |
26.8.2011 |
EU/1/06/349/001–010 |
Avaglim |
Norra |
18.8.2011 |
V LISA
Peatatud müügilubade nimekiri
Ajavahemikus 1. juulist – 31. detsembrini 2011 peatati EMP EFTA riikides järgmised müügiload:
ELi number |
Toode |
Riik |
Peatamise kuupäev |
EU/1/06/361/001–002 |
Luminity |
Liechtenstein |
31.12.2011 |
EU/2/08/088/001–003 |
Acticam |
Island |
23.8.2011 |